BR112012004862A2 - Method for the preparation of a compound, crystalline duloxetine, and pharmaceutical composition - Google Patents

Method for the preparation of a compound, crystalline duloxetine, and pharmaceutical composition

Info

Publication number
BR112012004862A2
BR112012004862A2 BR112012004862A BR112012004862A BR112012004862A2 BR 112012004862 A2 BR112012004862 A2 BR 112012004862A2 BR 112012004862 A BR112012004862 A BR 112012004862A BR 112012004862 A BR112012004862 A BR 112012004862A BR 112012004862 A2 BR112012004862 A2 BR 112012004862A2
Authority
BR
Brazil
Prior art keywords
compound
preparation
pharmaceutical composition
crystalline duloxetine
duloxetine
Prior art date
Application number
BR112012004862A
Other languages
Portuguese (pt)
Inventor
Hana Brusová
Josef Cinibulk
Ludek Ridvan
Veronika Grüwaldová
Original Assignee
Zentiva Ks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva Ks filed Critical Zentiva Ks
Publication of BR112012004862A2 publication Critical patent/BR112012004862A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
BR112012004862A 2009-09-02 2010-09-02 Method for the preparation of a compound, crystalline duloxetine, and pharmaceutical composition BR112012004862A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2009-584A CZ304602B6 (en) 2009-09-02 2009-09-02 Crystallization process of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine hydrochloride)
PCT/CZ2010/000099 WO2011026449A1 (en) 2009-09-02 2010-09-02 A method of crystallization of (s)-n-methyl-3-(1-naphthyloxy)-3- (2-thienyl)propylamine hydrochloride (duloxetine)

Publications (1)

Publication Number Publication Date
BR112012004862A2 true BR112012004862A2 (en) 2015-09-08

Family

ID=43413356

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012004862A BR112012004862A2 (en) 2009-09-02 2010-09-02 Method for the preparation of a compound, crystalline duloxetine, and pharmaceutical composition

Country Status (11)

Country Link
EP (1) EP2473497A1 (en)
JP (1) JP2013503823A (en)
KR (1) KR20120047262A (en)
CN (1) CN102482254A (en)
BR (1) BR112012004862A2 (en)
CZ (1) CZ304602B6 (en)
EA (1) EA021528B1 (en)
IL (1) IL218329A0 (en)
MX (1) MX2012002621A (en)
WO (1) WO2011026449A1 (en)
ZA (1) ZA201201570B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103626735A (en) * 2012-08-28 2014-03-12 石药集团中奇制药技术（石家庄）有限公司 Duloxetine hydrochloride crystal form and preparation method thereof
CN104478849A (en) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 Method for preparing noradrenaline reuptake dual inhibitor
CN106265528A (en) * 2015-05-12 2017-01-04 法德生技药品股份有限公司 The method preparing medicine agglutination body
JP2016222628A (en) * 2015-06-03 2016-12-28 株式会社トクヤマ Method for producing duloxetine hydrochloride

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR880007433A (en) 1986-12-22 1988-08-27 메리 앤 터커 3-aryloxy-3-substituted propanamine
US5362886A (en) 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
DE10212301A1 (en) 2002-03-20 2003-10-02 Bayer Ag Process for the preparation of aryl aminopropanols
DE60329640D1 (en) 2002-07-09 2009-11-19 Lonza Ag Process for the preparation of N-monoalkyl-beta-aminoalcohols
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
CZ297560B6 (en) * 2004-10-26 2007-02-07 Zentiva, A. S. Process for preparing (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine hydrochloride (duloxetine)
TW200639162A (en) * 2005-03-14 2006-11-16 Teva Pharma Pure duloxetine hydrochloride
EP1820800A1 (en) * 2006-02-17 2007-08-22 KRKA, tovarna zdravil, d.d., Novo mesto Crystalline forms of duloxetine hydrochloride and processes for their preparation
GB0612508D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
GB0612509D0 (en) * 2006-06-23 2006-08-02 Arrow Int Ltd Crystalline duloxetine hydrochloride
CZ300116B6 (en) * 2006-12-05 2009-02-11 Zentiva, A. S. Purification process of (S)-N-methyl-3-(1-naphtyloxy)-3-(2-thienyl) propylamine hydrochloride
EP2132192B1 (en) * 2007-03-05 2013-04-24 Lupin Limited Novel process for preparation of duloxetine hydrochloride

Also Published As

Publication number Publication date
CZ2009584A3 (en) 2011-03-09
JP2013503823A (en) 2013-02-04
ZA201201570B (en) 2013-08-28
EP2473497A1 (en) 2012-07-11
EA021528B1 (en) 2015-07-30
KR20120047262A (en) 2012-05-11
IL218329A0 (en) 2012-04-30
CZ304602B6 (en) 2014-07-30
EA201290127A1 (en) 2013-02-28
CN102482254A (en) 2012-05-30
MX2012002621A (en) 2012-07-03
WO2011026449A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
BRPI0909691A2 (en) Compound, method for preparing a compound, and pharmaceutical composition
BRPI1011764A2 (en) pharmaceutical composition and method for preparing a pharmaceutical composition
BRPI0818533A2 (en) compound, pharmaceutical composition, and process for the preparation of a compound
BRPI0817423A2 (en) Processes for preparing a compound, for preparing a pharmaceutical formulation, and for preparing an intermediate of a compound, and, compound
BR112014007645A2 (en) heterocyclic compound, methods for preparing a heterocyclic compound, and pharmaceutical composition
BRPI0917196A2 (en) method for preparing a complex, and, crystalline form of a compound.
BRPI1010775A2 (en) composition, method for preparing a composition, and use of a composition.
BRPI1016219A2 (en) compound, pharmaceutical composition, and use of a compound
BRPI1008793A2 (en) compound use of a compound and pharmaceutical composition
BR112014003802A2 (en) compound, compound pharmaceutical composition, use of a compound, method for making a compound, and preparation of a medicament
BRPI0918971A2 (en) thienopyrimidines for pharmaceutical compositions
BRPI0922566A2 (en) crystalline polymorph, pharmaceutical composition, compound, and methods for preparing a compound, and for treating a disease.
BRPI1010933A2 (en) process for the preparation of a powder and, compound
BRPI0906475A2 (en) Compounds, process for preparing a compound, pharmaceutical composition and use of a compound
BRPI1016132A2 (en) composition, pharmaceutical formulation, method for manufacturing a stable pharmaceutical formulation.
BRPI0613574A2 (en) isolated crystalline form of a compound, method for preparing a compound, and pharmaceutical composition
BR112012002102A2 (en) pharmaceutical composition and method for preparing a pharmaceutical composition
BR112013008008A2 (en) compound, pharmaceutical composition and process for preparing a compound
BR112012004173A2 (en) "compound, composition, method for preparing a composition, and use of a compound"
BRPI1012978A2 (en) topical composition, method for preparing it, and use of a compound
BRPI0922173A2 (en) pharmaceutical preparation and method for preparing a pharmaceutical preparation
BRPI1007161A2 (en) oral pharmaceutical composition, and process for preparing a composition
BRPI0814163A2 (en) PROCESS FOR PREPARATION OF COMPOUNDS, CRYSTALLINE FORM, AND PHARMACEUTICAL COMPOSITION
BRPI1007624A2 (en) compound, method of preparing a pharmaceutically acceptable salt, composition or salt thereof and use of a pharmaceutically acceptable salt or compound thereof
BRPI0918955A2 (en) solid preparation, and method for stabilizing a compound, and for improving dissoulution of a compound

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.